Alnylam Interview: RNAi Leader Expands Into NASH, CNS And Eye Diseases

Buoyed By $1bn Regeneron Alliance

08 Jan 2020

• By Andrew McConaghie

Feature article: Alnylam’s R&D leader Akshay Vaishnaw sets out plans for next-generation gene-silencing therapies.

Alnylam — Alnylam's Boston, MA headquarters. It will take another 5-10 years for Alnylam to enter biopharma's 'big league' - but it has already put RNAi on the map • Source: Photo Courtesy of BioMed Realty, L.P. All Rights Reserved

More from Alimentary/Metabolic

More from Therapy Areas